Umang Vohra - Dr Reddys Insider

RDY -- USA Stock  

USD 29.84  0.06  0.20%

Executive Vice President Head - North America Generics
Mr. Umang Vohra is Executive Vice President Head North America Generics of Dr. Reddy Laboratories Ltd since January 2013. He resigned as Chief Financial Officer of the company effective January 2 2013. He has over 14 years of experience across various functions within finance strategic planning and corporate development. He is responsible for managing Company organizations global finance functions including among others Accounts and Controlling Taxation Compliance Secretarial Investor Relations and Treasury. He joined the Company in 2002 initially working as Deputy Chief Financial Officer and was part of several of Company key initiatives like acquisitions research and development derisking transactions and operational improvements and migration to IFRS in Company accounting governance and finance processes. Prior to joining the Company Mr. Vohra worked with Eicher and PepsiCo India
Age: 43  President Since 2013  MBA    
91 40 4900 2900  http://www.drreddys.com
Vohra has a base degree in computer engineering and he holds an MBA with a specialization in Finance from TA Pai Institute of Management, India.

Management Efficiency

The company has Return on Asset of 3.49 % which means that on every $100 spent on asset it made $3.49 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 7.83 % implying that it generated $7.83 on every 100 dollars invested.
The company has 741.44 M in debt with debt to equity (D/E) ratio of 40.1 . This implies that the company may be unable to create cash to meet all of its financial commitments. Dr Reddys Laboratories Limited has Current Ratio of 1.54 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

PRESIDENT Since

John MageeFlexion Therapeutics
2016
Daniel RudioEndo International plc
N/A
Matthew MalettaEndo International plc
2015
Michael MarinoFibrocell Science
2015
Blaise ColemanEndo International plc
2016
Matthew DOnofrioEvoke Pharma
2010
Patrick BarryEndo International plc
2018
Joel SabanDiplomat Pharmacy
2017
Atheer KaddisDiplomat Pharmacy
2016
Gary RiceDiplomat Pharmacy
2016
Keith GoldanFibrocell Science
2016
Paul UrickDiplomat Pharmacy
2016
Wayne SwantonAllergan plc
2017
Brian LortieEndo International plc
N/A
Gary KadlecDiplomat Pharmacy
2016
Carrie NicholEndo International plc
2018
Antonio PeraEndo International plc
2016
Terrance CoughlinEndo International plc
2016
Mark LevineFlexion Therapeutics
2017
Mark FragaFlexion Therapeutics
2017
Adrian HepnerEagle Pharmaceuticals
2016

Entity Summary

Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug Manufacturers - Specialty Generic classification in USA and traded on New York Stock Exchange. It employs 23524 people.Dr Reddys Laboratories Limited (RDY) is traded on BATS Exchange in USA. It is located in INDIA and employs 23,524 people. Dr Reddys is listed under Pharmaceutical Products category by Fama And French industry classification.

Dr Reddys Laboratories Leadership Team

G Prasad, Chairman
Hans Hasler, Director
Sandeep Poddar, Executive, Ph.D
Satish Reddy, Chairman
Kedar Upadhye, Executive
Samiran Das, President, Ph.D
Amit Biswas, President, MBA
Ravi Bhoothalingam, Director
Alok Sonig, President, MBA
J Ramachandran, President
Prasad Menon, Director
K Rao, President
Abhijit Mukherjee, COO, Ph.D
Saumen Chakraborty, CFO
Sridar Iyengar, Director, Ph.D
Ganadhish Kamat, President
Sripada Chandrasekhar, President, MBA
Omkar Goswami, Director
Erez Israeli, COO
Kalpana Morparia, Director, MBA
Bharat Doshi, Director, MBA
J Moreau, Director, Ph.D
Raghav Chari, President, Ph.D
Bruce Carter, Director, Ph.D
Saunak Savla, Executive
Ashok Ganguly, Director, Ph.D
Umang Vohra, President, MBA
M Ramana, President, MBA
Cartikeya Reddy, President
Anupam Puri, Director

Stock Performance Indicators

Did you try this?

Run Focused Opportunities Now
   

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Focused Opportunities
Currently Active Assets on Macroaxis
C   
Purchased over 40 shares of
few hours ago
Traded for 67.0
ITTOF   
Purchased over 100 shares of
few hours ago
Traded for 23.2
GOOG   
Purchased few shares of
few hours ago
Traded for 1188.8199
CRM   
Purchased over 20 shares of
few hours ago
Traded for 147.61
GOOG   
Purchased few shares of
few hours ago
Traded for 1188.8199
Additionally take a look at Your Equity Center. Please also try Coins and Tokens Correlation module to utilize digital token correlation table to build portfolio of cryptocurrencies across multiple exchanges.